Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Jeffrey Paul, PhD

Jeffrey Paul, PhD

Principal at JPharm Consulting

Connect with Jeffrey Paul, PhD on LinkedIn

About the author: Dr. Paul is a clinical pharmacology consultant to the pharmaceutical industry, focusing his practice on early clinical development of drugs for CNS and pain. Dr. Paul has spent nearly 30 years in pharmaceutical R&D, including Discovery, and Phase 1 through 4 clinical development phases. He has global clinical and regulatory experience, especially in Europe and Japan. He has worked at Berlex, Pfizer (formally Wyeth), and Astellas at the Executive Director/Assistant VP level. Dr. Paul has an adjunct faculty appointment at Drexel Medical College (Philadelphia) where he teaches in the graduate Drug Discovery and Development program and Neuropharmacology courses; and is active in Drexel’s Clinical Research for Health Professionals Program and Clinical & Translational Research Institute. Dr. Paul is also active in promoting translation medicine as a member of the Executive Committee of Translation, Clinical Pharmacology Division of American Society for Pharmacology & Experimental Therapeutics (ASPET).

Posts by Jeffrey Paul, PhD

Linking Disease Biology to Novel Drug Targets

Posted on June 22nd, 2016 in Pharma R&D

Discovering novel drug targets is complicated, and we all know about their low success rate in the clinic. (more…)

Sources of Innovation for Drugs of the Future

Posted on June 6th, 2016 in Pharma R&D

Innovative drug targets are necessary if precision medicine is to become the norm. Collaboration will be the enabler in developing novel drug therapies: (more…)

  1. 1
  2. 2
  3. 3